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Abstract.  Tightly controlled proteolytic degradation of 
the extracellular matrix by invading microvascular en- 
dothelial cells is believed to be a necessary component 
of the  angiogenic  process.  We  have  previously  dem- 
onstrated the induction of plasminogen activators 
(PAs) in bovine microvascular endothelial (BME) cells 
by three agents that induce angiogenesis in vitro: basic 
FGF (bFGF), PMA, and sodium orthovanadate.  Sur- 
prisingly,  we find that these agents also induce plas- 
minogen activator inhibitor-1  (PAI-1) activity and 
mRNA in BME cells. We also find that transforming 
growth factor-#l  (TGF-BI), which in vitro modulates 
a number of endothelial cell functions relevant to 
angiogenesis,  also increases both PAI-1 and urokinase- 
type PA (u-PA)  mRNA.  Thus, production of both 
proteases and protease inhibitors is increased by an- 
giogenic agents and TGF-B1.  However, the kinetics 
and amplitude of PAI-1 and u-PA mRNA induction by 
these agents are strikingly different. We have used the 
ratio of u-PA:PAI-1  mRNA levels as an indicator of 
proteolytic balance.  This ratio is tilted towards en- 
hanced proteolysis in response to bFGF, towards an- 
tiproteolysis in response to TGF-B1,  and is similar to 
that in untreated cultures when the two agents are 
added simultaneously.  Using an in vitro angiogenesis 
assay in three-dimensional  fibrin gels, we find that 
TGF-B1  inhibits the bFGF-induced formation of tube- 
like structures,  resulting in the formation of solid en- 
dothelial cell cords within the superficial parts of the 
gel.  These results suggest that a net positive proteo- 
lytic balance is required for capillary lumen forma- 
tion.  A  novel perspective is provided on the relation- 
ship between extracellular matrix  invasion,  lumen 
formation,  and net proteolytic balance, thereby reflect- 
ing the interplay between angiogenesis-modulating 
cytokines such as bFGF and TGF-/31. 
D 
JRING angiogenesis,  the process of new blood vessel 
formation,  microvascular  endothelial  cells are be- 
lieved to respond to angiogenic  stimuli  by locally 
degrading the basement membrane of the parent vessel, and 
subsequently  invading  the  interstitial  extracellular  matrix 
in which they form tubular capillary sprouts  (Cliff,  1963; 
Schoefl, 1963; Ausprunk and Folkman, 1977). In an attempt 
to recapitulate  some of these early angiogenic events in vitro, 
we have developed an experimental model in which micro- 
vascular endothelial  cells can be induced to invade a three- 
dimensional  collagen  matrix and to form capillary-like  tu- 
bular structures (Montesano and Orci,  1985).  Agents  that 
induce this phenomenon include the tumor promoter PMA 
(Montesano  and Orci,  1985),  basic FGF (bFGF)  t (Mon- 
tesano et al., 1986), and sodium orthovanadate,  an inhibitor 
of phosphotyrosine phosphatases (Montesano et al., 1988). 
1. Abbreviations usedin thispaper: bFGF, basic FGF; BME, bovine micro- 
vascular endothelial; CPAE,  calf pulmonary artery endothelial; PA, plas- 
minogen activator;  PAId,  PA  inhibitor-l; TGF-fl,  transforming growth 
factor-B. 
Transforming  growth factor-# (TGF-/3), on the other hand, 
has been shown to inhibit PMA-induced invasion of a colla- 
gen matrix (MOiler et al., 1987; and R. Montesano,  unpub- 
lished observation). 
One mechanism which is believed to facilitate cellular in- 
vasion is the limited proteolytic degradation  of matrix com- 
ponents  at regions  of close proximity between cell surface 
and the surrounding  extracellular  matrix.  Plasminogen  acti- 
vators (PAs) are considered to be key mediators in the inva- 
sion process; they convert the widely distributed and proteo- 
lytically inactive  plasminogen  to active  plasmin,  a tryptic 
protease capable of directly degrading  certain matrix com- 
ponents  and  activating  other  matrix-degrading  proteases 
such as coUagenase (Saksela  and Rifkin,  1988; Moscatelli 
and Rifkin, 1988). The necessity of limiting the extent of ma- 
trix degradation has previously been suggested by our obser- 
vation that the neutralization  of excess proteolytic activity is 
an absolute requirement for maintaining  an intact fibrin ma- 
trix scaffold, into which stimulated endothelial  ceils migrate 
to form tube-like structures in vitro (Montesano et al., 1987). 
In vivo, plasmin inhibitors  such as alpha2-antiplasmin  and 
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effect.  PA inhibitor-1  (PAI-1), a  major endothelial-derived 
component of the subendothelial matrix (Rheinwald et al., 
1987; Levin and Santell, 1987; Mimuro et al., 1987; Mimuro 
and Loskutoff, 1989),  is also believed to protect extracellu- 
lar matrix proteins from uncontrolled PA-catalyzed proteol- 
ysis (Laiho et al.,  1986;  Knudsen et al.,  1987; Levin and 
Santell,  1987; Mimuro et al.,  1987; P611~inen et al.,  1987; 
Knudsen and Nachman,  1988;  Sakata et al.,  1988). 
It has previously been demonstrated that agents that are 
angiogenic in our in vitro system increase the production of 
PAs, and in particular u-PA,  in microvascular endothelial 
cells (Gross et al.,  1982,  1983;  Montesano et al.,  1986; 
Moscatelli,  1986;  Moscatelli et al.,  1986;  Presta  et al., 
1986; Montesano et al., 1988). Prompted by the apparently 
paradoxical finding that the physiological angiogenesis fac- 
tor  bFGF  also  induces  the  protease  inhibitor  PAI-1 in 
microvascular endothelial cells (Saksela et al.,  1987),  we 
wished to determine how the potential proteolytic balance, 
as reflected by the ratio of u-PA:PAI-1 steady-state mRNA 
levels,  changes in cells exposed to agents which have been 
shown to modulate angiogenesis in vitro. Using our previ- 
ously described  model  of in  vitro angiogenesis,  we  also 
wished to determine the relationship between extracellular 
matrix invasion and lumen formation, two necessary compo- 
nents  of  the  angiogenic  process,  and  extracellular  pro- 
teolysis. 
Materials and Methods 
Cells and Materials 
Cloned bovine microvascular endothelial (BME)  cells derived from the 
adrenal cortex (Furie et at., 1984) were generously provided by Drs. M. B. 
Furie and S. C. Silverstein (Columbia University, New York) and were rou- 
tinely cultured as previously described (Montesano and Orci, 1985).  Calf 
pulmonary artery endothelial (CPAE) cells obtained from American Type 
Culture Collection (Rockville, MD) were cultured as described (Montesano 
and Orci,  1987).  The eDNA probes for human PAl-I, mouse laminin B1 
chain, and rat actin were kindly provided by Drs. P. Andreasen and E  Blasi 
(University of Copenhagen, Denmark), Dr. B. L. Hogan (Vanderbilt Uni- 
versity, Nashville, TN), and Dr. G. Gabbiani (University of Geneva, Swit- 
zerland), respectively, bFGF was a generous gift from Drs. A. Baird and 
R. Guillemin (The Sulk Institute, La Jolla, California), and human plate- 
let-derived TGF-B1 was kindly provided by Drs. M. Sporn and A. Roberts 
(National Cancer Institute, Bethesda, Maryland). All other reagents were 
as previously described (Montesano and Orci,  1985;  Montesano et al., 
1986,  1988). 
Zymographic and Reverse Zymographic Assays 
for PA and PAI4 
BME or CPAE cells were grown to confluence in gelatin-coated 35-mm cul- 
ture dishes, and the medium changed 24 h before addition of  the compounds 
to be tested. PMA (20 ng/ml), bFGF (30 ng/ml), sodium orthovanadate (20 
/zM) or TGF-B1 (1 ng/ml) were added to separate dishes and the cells in- 
cubated at 370C for 15 h. The dishes were washed, and 2 ml of serum-free 
medium containing Trasylol (200 KIU/ml) together with the compounds to 
be tested, was added to the dishes. After a further 3-h incubation, cell ex- 
tracts and culture supernatants were prepared as previously described (Mon- 
tesano et al., 1986). For reverse zymographic assays (Loskntoff et al., 1983), 
samples were incubated with 0.5% SDS, 0.5%/3-mercaptoethanol for 1 h 
at 37°C to neutralize PA activity (Sakata et al., 1988).  20-#1 aliquots were 
then subjected to SDS-PAGE, and zymographic analysis using a casein- and 
plasminogen.-containlng  substrate gel was performed as previously described 
(Vassalli et al., 1984).  0.05 U/nil human urokinase (Serono, Denens, Swit- 
zerland) was also added to substrate gels for reverse zymographic analysis. 
Zymograms and reverse zymograms were photographed under dark ground 
illumination after incubation at 37°C. 
RNA Extraction 
Endothelial cells were grown to confluence in gelatin-coated 100-mm tissue 
culture  dishes.  Fresh  complete  medium  was  added  to  the  confluent 
monolayers 24 h before adding the agents to be tested, and was not changed 
thereafter. PMA (10-20 ng/ml); bFGF (10-30 ng/ml), sodium orthovana- 
date (20 ~M) or TGF-B1 (2 or 5 ng/ml), were added to separate dishes and 
total cellular RNA extracted according to a modification of the method of 
Glisin et al.  (1974)  as described previously (Montesano et al.,  1988). 
Plasmid Construction and In Vitro Transcription 
pSP64-mUK: a  652 bp Pst I-Hind HI fragment (positions 427-1,078)  of 
mouse u-PA eDNA clone pDB15  (Belin et al.,  1985),  was subcloned into 
pSP64 (Melton et al.,  1984). 
pSP64-hPAl-l: a  1.4-Kbp Eco RI-Bgl II fragment (positions 54-1,480 
from Pannekoek et al., 1986) isolated from pPAI1-C1, a plasmid containing 
a 2.2-Kbp human PAI-1 eDNA insert (Andreasen et al.,  1986),  was sub- 
cloned between the Barn H1  and Eco RI sites of pSP64 (Melton et al., 
1984). 
pSP65-hTA:  a 614-bp Bgl II-Eco RI fragment (positions 188-801)  iso- 
lated from pW349F, a plasmid containing a 2.6-Kbp human tissue-type PA 
(t-PA) cDNA insert (Fisher et al.,  1985),  was subcloned between the Eco 
RI and Bum HI sites of pSP65 (Melton et al.,  1984). 
pSP65-mLBl: a 920-bp Bgl II-Eco RI fragment (positions 200-1,120) 
isolated from pPE49, a plasmid containing a  1.1-Kbp mouse laminin B1 
chain cDNA insert (Barlow et al., 1984),  was subcloned between the Eco 
RI-Bam HI sites of pSP65 (Melton et al.,  1984). 
pRAocxA-C: a 320-bp Bgl II-Ava II fragment from the coding region of 
rat a-smooth muscle actin (Kocher and Gabbiani, 1987), was subcloned be- 
tween the Sma I and Bum HI sites of pSP65 (Melton et al.,  1984),  after 
filling in the Ava II site with the Klenow fragment of DNA polymerase 
(Kocher and Gabbiani, 1987).  Although derived from an or-smooth muscle 
actin eDNA, this probe recognizes mRNA from all actin species (Kocher 
and Gabbiani,  1987). 
pSP64P1-01:  a 600-bp Eco RI-Pst I fragment of bovine PAl-1 clone P1 
designated P1-01 (see below and Fig. 1 a), was subcloned between the Pst I 
and Eco RI sites of pSP64 (Melton et al.,  1984). 
pSP64-mUK,  pSP64-hPAI-1,  pSP65-hTA,  pSP65-mLB1,  pRAotxA-C, 
and pSP64PI-01 were linearized respectively with Hinc II, Eco RI, Hind 
III, Hinc II, Xba I, and Eco RI, and used as templates for bacteriophage 
SP6 RNA polymerase (Melton et al., 1984).  Transcription was performed 
exactly as described by Busso et al.  (1986). 
Northern Blot Hybridization 
Total cellular RNA was denatured with glyoxal, electrophoresed in a 1.2 % 
agarose gel (5 /~g RNA per lane), and transferred overnight onto nylon 
membranes (Hybond; Amersham International pie, Buckinghamshire, UK) 
as described by Thomas (1980).  All filters were baked under vacuum at 
80°C for 2 h, and some were also exposed to UV (302  nm) for 30 s. All 
filters were stained with methylene blue to reveal 18S and 28S rRNAs; only 
those filters which showed uniform loading of total RNA, as revealed by 
methylene blue staining, were subsequently hybridized. Filters were boiled 
for 5 min in 20 mM Tris-HCl, pH 8.1, to remove residual glyoxal. The 
filters were prehybridized for 6 h at 65°C and hybridized at 65°C with 2 
×  106 cpm/ml of 32P-labeled probe for 18 h as described (Busso et al., 
1986).  The filters were washed twice at 65°C with 3x  SSC (ix  SSC  = 
0.15 M NaCI, 0.015 M Na citrate, pH 7.0), 2 × Denhardt's solution (Maniatis 
et al.,  1982),  and three times at 70°C (u-PA, t-PA, laminin B1, and total 
actin) or 75"C (PAl-I) with 0.2x  SSC, 0.1% SDS, and 0.1% sodium pyro- 
phosphate. Filters were exposed to Kodak XAR-5 films at room temperature 
or  -80°C between intensifying screens. Autoradiographs were scanned 
with a GenoScan laser scanner (Genofit, Geneva, Switzerland). 
Cloning of  a Bovine PAI-1 cDNA 
Double-stranded eDNA was prepared from 2/~g of poly(A)  + RNA from 
BME cells treated for 8 h with PMA (20 ng/ml) using a eDNA synthesis 
kit (Amersham Corp). cDNAs were size fractionated on a 5-20% sucrose 
gradient, and DNA greater than 2.0 Kb was tailed with dGTP. pUC19 was 
linearized with PstI, tailed with •20  dC residues, and annealed to dGTP- 
tailed cDNAs. The DNA was transformed into MAX Efficiency DH5  TM 
Competent Cells (Rethesda Research Laboratories, Basel, Switzerland). 
12,600 colonies were screened with a 32PdCTP random-prime labeled hu- 
man PAI-1 eDNA probe (Andreasen et al., 1986),  and a single colony, P1, 
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HV  P  V  B  S 
P1-01 
H  P 
#  I 
t  I  200  bp 
b. 
5'  sequence 
1  GAG  AGA 
Glu Arg 
46  AAA GGC 
LMs Gly 
91  CTG  ACA 
Leu Thr 
136  TGG  AAG 
Trp Lys 
181  CAC  AAG 
HiS Lys 
226  ACC AAC 
Thr ASh 
GCC AGG TTC  ATC GTC AAC GAC TGG GTG AAA AGA CAC ACA 
Ala Arg Phe Ile Val Asn Asp Trp Val Lys Arq His Thr  15 
ATG ATC AGC  GAC TTA CTT GGT GAA GGG  GCT  GTG GAC  CAG 
Met Ile Ser Asp Leu Leu Gly Glu Gly Ala  Val  Asp Gln  30 
CGC  CTG GTC CTG GTAAAT  GCC  CTC TAC  TTC AAC GGC  CAG 
Arg Leu Val  Leu Val Asn Ala  Leu Tyr Phe Asn GIy  Gln  45 
ATG  CCC TTC  CCA GAG TCA AAC ACC  CAC CAC  CGC  CTC TTC 
Met Pro Phe Pro Glu Set Asm Thr His His Arg Leu Phe  60 
TCC  GAT  GGC AGC ACC ATC TCT GTG  CCC ATG  ATG GCT  CAG 
Ser Asp Gly Ser Thr Ile Ser Val Pro Met Met Ala  Gln  75 
AAG TTC AAC TAC ACT GAG 
Lys Phe ASh Tyr Thr Glu 
3  * sequence 
1  TGT  TTT 
46  AGC  CAC 
91  TTG  CTT 
136  TTT AAA 
181  AAA AAA 
GTT  TTG TTT TTC TTT TTT  CTT GAT GCA  CTG GAC  AGT  GAC 
ACT  CAG TAC  CCC CAC GTG TGG GGT CCA TGG  CTC TTG AAA 
TTT  CAC TTT TGA TAT AGA AGC AAG  TAA AAA AAA  ATG  TTT 
AAT TAA TAA TAA ATA AAT AAA AAG AAT ATT  CCA AAA  TAA 
AAA AAA A 
Figure L (a) Restriction map of bovine PAI-I cDNA isolate P1. Re- 
striction enzymes (H) Hinc II; (V) Pvu II; (P) Pst I; (B) Barn HI; 
(S) Sma I. P1-01, a 600-bp  internal  Hinc II-Pst I fragment of P1, 
was used to probe Northern blots and also in the nuclear run-on 
experiment shown in Fig. 6  a.  (b) Nucleotide and amino acid se- 
quences (numbers indicated on the left and right, respectively) of 
the 5' and 3' ends of P1. The nucleotide sequences of the 5' and 3' 
ends of bovine PAI-1 clone PI will appear in the EMBL data library 
under accession numbers  x52907  and  ×52906,  respectively. 
containing a 2.5 Kb insert of bovine PAl-l, was obtained. P1 was analyzed 
by restriction  enzyme mapping, and the indicated sites (Fig. I a) correspond 
exactly to those in a recently published bovine PAI-1 cDNA (Mimuro et al., 
1989).  Nucleotide  sequencing  was carried  out on  plasmid  DNA  by  the 
dideoxy  method using the Sequenase Kit version  2.0  (United  States Bio- 
chemical, Lucerne, Switzerland). The 5' sequence of P1 (nucleotides 1-249) 
is identical to nucleotides 578-826  of the bovine PAI-I  cDNA of Mimuro 
et al. (1989) (Fig. 1 b). The 3' end of P1 contains a poly-(A) tail; no sequence 
differences were found in the 3' sequence when compared to the published 
sequence  (nucleotides  2780-2957)  in Mimuro et al.  (1989)  (Fig.  1 b). 
Nuclear Run-on Transcription Analysis 
Clone P1-01,  containing a 600-bp  internal Hinc II-Pst I fragment derived 
from clone P1 (Fig.  1 a), was subcloned into pUC9, and used for analysis 
of PAI-I transcription  in BME cells. Nuclei were prepared  from BME cells, 
transcripts  elongated  in  vitro,  and  newly  synthesized  RNA  (3.75  x  t06 
cpm/filter)  was hybridized  to  plasmid  DNA  (2  /~g/dot)  immobilized  on 
nitrocellulose,  for 40 h at 65°C  (Collart et al.,  1987).  Filters  were subse- 
Figure 2.  Induction of PAI-1 activity  and  mRNA  by  angiogenic 
agents.  (a) Reverse zymography. PAI-1 is increased in cell extracts 
and culture supematants after treatment of confluent monolayers of 
BME cells with PMA (P), bFGF (F), or vanadate  (I,9. (b) North- 
ern blot hybridization of total cellular RNA. Steady-state levels of 
PAI-1  and  u-PA  mRNAs  are increased after 8  h  of treatment of 
confluent monolayers of BME cells with PMA (P), bFGF (F), or 
vanadate (V). Shown in the lower panel are the same filters stained 
with methylene blue before hybridization, which reveals uniform 
loading of total cellular RNA. 28S and  18S ribosomal markers are 
indicated. 
quently washed as described (Collart et al.,  1987), and exposed at -80°C 
to Kodak XAR film between intensifying  screens. 
In Vitro Angiogenesis Assay 
BME or CPAE cells were seeded onto three-dimensional  fibrin  gels, pre- 
pared in 18-mm tissue culture wells (Nunc, Roskilde, Denmark) as previ- 
ously described (Montesano et aL, 1987), and grown to confluence in com- 
plete medium. At confluence, bFGF (30 ng/ml), TGF-/~ (5 ng/ml), or both 
agents together,  were added to the cultures in the presence or absence of 
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u-PA mRNAs by bFGE Northern blots of total 
cellular RNA from BME cells demonstrate a 
time-related decrease in PAI-1 and increase in 
u-PA mRNA levels in control cultures. PAI-1 
and u-PA mRNA are maximally induced after 
4 and 24 h in response to bFGF, respectively. 
In contrast, no increase in t-PA mRNA levels 
is seen until 48 h. 
the serine protease inhibitor,  Trasylol (200 KIU/ml).  Medium and com- 
pounds were changed every 2-3 d, and the cultures were fixed in situ after 
1 wk in 2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer (pH 7.4), 
and photographed under phase contrast using a Nikon Diaphot TMD in- 
verted photomicroscope. 
Processing  for Light Microscopy 
Cultures which had been fixed in situ overnight were extensively washed 
in 0.1 M sodium cacodylate buffer (pH 7.4). Fibrin gels were then cut into 
2 × 2 mm fragments, and the fragments postfixed in 1% osmium tetroxide 
in Veronal acetate buffer for 45 min, and processed further as previously 
described (Montesano and Orci, 1985). Semi-thin sections were cut perpen- 
dicular to the culture plane with an LKB ultramicrotome,  stained with 1% 
toluidine blue, and photographed under transmitted light using an Axiophot 
photomicroscope  (Zeiss, West Germany). 
Results 
Induction of  PAI-1 and u-PA by Angiogenic Agents 
PAI-1 production by BME cells was studied by reverse zymo- 
graphic analysis (Loskutoff et al.,  1983). The white bands 
seen under dark-ground illumination result from the retarda- 
tion of substrate lysis by PAI-1 which has diffused from an 
overlying polyacrylamide gel into a zymographic underlay 
containing u-PA, plasminogen,  and casein as an indicator 
substrate. A single 48-kD inhibitor corresponding to the bo- 
vine PAI-1 previously described in microvascular endothelial 
cells (Saksela et al.,  1987) was seen in the cell extracts of 
control cultures (Fig. 2 a).  PAI-1 activity was increased in 
both cell extracts and culture media after treatment of BME 
cells with  either PMA  (20 ng/ml),  bFGF  (30  ng/ml),  or 
vanadate (20 t~M) (Fig. 2 a). 
Northern blot analysis revealed a single PAI-1 mRNA spe- 
cies in untreated cultures after hybridization of total cellular 
BME RNA  with a  32P-labeled human PAI-1 eDNA probe 
(Fig. 2 b). An increase in the level of PAI-1 mRNA was seen 
after treatment for 8  h  with PMA  (20 ng/ml),  bFGF  (30 
ng/ml), or vanadate (20/~M). The same RNAs were also hy- 
bridized with a murine u-PA probe; as expected from previ- 
ous findings (Montesano et al.,  1988), all three agents in- 
duced an increase in the levels of u-PA mRNA  (Fig.  2b). 
Thus,  all three agents increased the mRNA levels of both 
u-PA and its inhibitor. 
To further explore the induction of both protease and in- 
hibitor by angiogenic agents,  a  kinetic analysis of mRNA 
levels was  performed.  This  revealed that  in  control  (un- 
treated) cultures, PAI-1 mRNA decreased while u-PA mRNA 
increased with time in culture (Fig. 3). In contrast, in cul- 
tures exposed to bFGF (10 ng/ml),  an initial increase and 
subsequent  decrease  in  PAI-1 mRNA  was  observed,  the 
highest level being achieved after 4 h. In the same samples, 
the  increase  in  u-PA  mRNA  levels  was  distinctly  more 
prolonged, maximal induction being after 24 h (Fig. 3). In 
contrast, the levels of t-PA mRNA were not increased until 
Figure 4. Kinetics of induction of PAI-1 and u-PA mRNAs by PMA 
and vanadate. PMA or vanadate (Van) maximally increase PAI-1 
and u-PA mRNA levels after 8 and 24 h, respectively. 
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Figure 5. Kinetics  of induction of PAI-1 and u-PA mRNAs by TGF- 
~1 (darkly shaded bars) and bFGF (lightly shaded bars). (Open 
bars =  control, untreated  cultures).  (a) Densitometric scans of au- 
toradiographs reveal that the steady-state  level of PAI-I mRNA is 
rapidly increased after exposure of BME cells to TGF-/~I, and at 
12 h reaches a maximum 39-fold increase  over control cultures  at 
12 h. In contrast, PAI-1 mRNA is maximally induced 3.6-fold by 
bFGF relative  to control cultures  at 4 h. (b) TGF-/31 initially  de- 
creases and subsequently  increases the level of  u-PA mRNA, which 
is maximally induced 12-fold relative  to control cultures  at 24 h; 
bFGF causes a rapid and sustained  increase in the u-PA mRNA 
level,  mRNA content at T  =  0 h is given an arbitrary value of 1. 
48 h  (Fig.  3).  These data were quantified by densitometric 
scanning (see Fig.  5). 
The kinetics of u-PA and PAI-1 mRNA induction by PMA 
(20 ng/ml) or vanadate (20/zM) were also explored.  After 
exposure to either of these two agents, the increase in PAI-1 
mRNA was followed by an early decline when compared to 
u-PA mRNA (Fig. 4).  Thus, in the presence of these two in 
vitro angiogenic agents, kinetics of induction similar to those 
achieved with the physiological angiogenesis factor, bFGF, 
are observed. 
Different Kinetics of  PAI-1 and u-PA mRNA Induction 
by bFGF and TGF-~I 
TGF-/5'I  (2-5  ng/ml) has previously been  shown to inhibit 
PMA-induced microvascular endothelial cell invasion of col- 
lagen gels (Miiller et al.,  1987; R. Montesano, unpublished 
observation),  u-PA and PAI-1 mRNA levels were analyzed 
Figure 6. (a) Stimulation  of PAI-1 transcription by bFGF in BME 
cells.  Nuclei were isolated  from control (C) or bFGF-treated (F) 
cultures at 0, 3, or 8 h. Labeled transcripts synthesized  in run-on 
transcription  assays  were hybridized to bovine PAI-1 (PI-01) or 
mouse laminin B1 chain (LB/) DNA immobilized on nitrocellulose. 
PAI-I transcription is maximal after 3 h treatment with bFGF (F3). 
Laminin BI chain transcription is not affected by treatment with 
bFGE pUC9 was used to determine background hybridization.  (b) 
Northern blot hybridization of total cellular BME RNA. Steady- 
state  levels of laminin B1 chain mRNA as revealed  with a mouse 
laminin  B1 chain cRNA probe are not altered after 12 h exposure 
to PMA (P), bFGF (F), or vanadate (V); the same RNAs hybrid- 
ized with a mouse u-PA cRNA probe reveal an increase in the levels 
of this  mRNA as expected  from Fig.  2 b. 
after exposure to 5 ng/ml of TGF-~I. A  quantitative kinetic 
analysis revealed that in contrast to the maximal fourfold in- 
crease at 4 h in response in bFGF (10 ng/ml), PAI-1 mRNA 
was  maximally  increased  39-fold  after  12  h  exposure  to 
TGF-~ when compared to controls at 12 h (Fig. 5 a). In the 
same samples,  a  12-fold increase  in u-PA mRNA was ob- 
served after 24 h  in the presence of TGF-/~I; in contrast to 
the rapid induction of u-PA mRNA by bFGF, the response 
to TGF-/~I  was relatively late  (Fig.  5  b). 
Transient Induction of PAI-1 Gene Transcription 
by bFGF 
Since the transient nature of  bFGF-induced PAI-1 mRNA in- 
crease  could  result  from  changes  in  transcription  and/or 
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ture  of PAI-1 mRNA induction,  bFGF  was  added to confluent 
monolayers of BME cells once (1), twice (2), or three times (3) at 
4-h intervals, and total RNA prepared after 12 hours. (C) Control 
cultures. Northern blots reveal that levels of PAI-1 mRNA were not 
further increased by repeated additions of bFGE (b) Pretreatment 
with bFGF does not affect induction of PAI-1 mRNA by TGF-/31 
(F/T). (C) Control; (F) bFGF-treated; and (T) TGF-/51-treated  cul- 
tures. BME cells were treated with bFGF for 4 h before addition 
of TGF-/31, and total cellular RNA was prepared  12 h later. 
mRNA stability, PAId transcription was determined in nu- 
clear run-on experiments.  It was  found that transcription 
from the PAI-1 gene was markedly increased after exposure 
to bFGF (30 ng/ml) for 3 h, and had declined by 8 h (Fig. 
6 a), reflecting the transient induction of PAI-1 mRNA seen 
in Figs.  3 and 5. In controls, PAl-1 transcription decreased 
with time in culture (Fig. 6 a). In contrast, no change was 
seen in the level of transcription of the B1 chain of laminin 
(Fig. 6 a), a finding which correlates with the lack of change 
in steady-state levels of  this mRNA in BME cells after a 12-h 
exposure to either PMA (10 ng/ml), bFGF (30 ng/ml),  or 
vanadate (20 #M) (Fig. 6 b). These results demonstrate that 
the  transient  increase  in  PAI-1 mRNA  levels can  be  ac- 
counted  for by  a  transient  increase  in  PAl-1 gene  tran- 
scription. 
To determine whether the transient nature of the PAl-1 
mRNA increase might be due to the disappearance of bFGF 
during the culture period, bFGF (10 ng/ml) was added to 
BME cultures at repeated 4-h intervals. No further increase 
in PAI-1 (Fig. 7 a) or u-PA (data not shown) mRNA levels 
was seen after repeated addition of bFGE Since the increase 
in u-PA and PAI-1 mRNA after a single dose of bFGF was 
refractory  to further additions of  this factor, it was of interest 
to determine whether pretreatment with bFGF might also 
render the cells refractory to additional stimulation by TGF- 
ffl. BME cells were therefore treated with bFGF (10 ng/mi) 
for 4 h, after which TGF-/31 (2 ng/ml) was added, bFGF or 
TGF-/31 were also added alone to separate dishes. Total cel- 
lular RNA extracted 12 h later was analyzed by hybridization 
of Northern blots. Pretreatment with bFGF did not inhibit 
the TGF-~-induced increase in PAl-1 mRNA (Fig. 7 b: com- 
pare lanes  T and F/T). 
Proteolytic Balance Correlates with Angiogenic or 
Antiangiogenic Responses In Vitro 
It has previously been demonstrated that TGF-~ (2-5 ng/ml) 
inhibits PMA-induced invasion of a three-dimensional colla- 
gen gel (Miiller et al., 1987; R. Montcsano, unpublished ob- 
servation). However, we thought it important to determine 
what effect TGF-~ might have on angiogenesis induced in 
vitro by the physiological angiogenesis  factor, bFGE  We 
have observed a concentration-dependent biphasic effect of 
TGF-~ on FGF-induced angiogenesis in vitro (5 ng/ml TGF- 
/31 inhibits invasion, while at 500 pg/ml, bFGF-induced inva- 
sion is potentiated; Pepper, M. S., R. Montesano, J.-D. Vas- 
salli, and L. Orci, manuscript in preparation); in this study 
we have chosen to examine the effects of TGF-/3 at the higher 
dose. Since the role of PA-catalyzed proteolytic activity might 
be more selectively explored under conditions which only 
require fibrinolysis, the in vitro angiogenesis assay was per- 
formed with fibrin rather than collagen gels. We have previ- 
ously shown that neutralization of excess fibrinolytic activ- 
ity, by addition of the serine protease inhibitor Trasylol, is 
an absolute requirement for maintenance of an intact fibrin 
matrix through which PMA-treated cells migrate to form 
capillary-like tubules; in the absence of Trasylol, the fibrin 
gel is completely lysed (Montesano et al., 1987). BME cells 
were grown to confluence on the surface of three-dimensional 
fibrin gels in the presence or absence of Trasylol, treated 
with bFGF (30 ng/ml), TGF-/$1 (5 ng/ml), or both agents to- 
gether, and invasion and tube formation assessed after 7 d. 
In control cultures in the presence (Fig.  8, a  and b) or ab- 
sence of Trasylol (not shown), the ceils remained confined 
to the surface of the gel, with the occasional formation of su- 
perficial short tube-like structures. In marked contrast, bFGF 
induced complete lysis of the gel in the absence of Trasylol 
(not shown), whereas addition of Trasylol resulted in the for- 
marion of  an extensive network of  branching and anastomos- 
ing tube-like structures within the gel, that were connected 
to the surface monolayer (Fig.  8, c and d).  When TGF-/$1 
was added alone (in the presence or absence of Trasylol), the 
cells remained confined to the surface of the gel (Fig.  8, e 
and f). When added together with bFGE TGF-/31 inhibited 
the gross bFGF-induced substrate lysis which occurs in the 
absence of Trasylol (not shown). In addition, TGF-/51 inhib- 
ited the formation of tube-like structures seen in response to 
bFGF in the presence of Trasylol (Fig. 8, g and h). Instead, 
either in the presence (Fig. 8, g and h) or absence (not shown) 
of Trasylol, apparent multilayering was seen, probably re- 
suiting from the migration of endothelial cells into the su- 
perficial parts of  the fibrin gel underneath the original mono- 
layer.  In  addition,  apparently  solid endothelial cell cords 
without lumina were also observed in the superficial parts of 
the gel (Fig. 8, g and h). Serial semi-thin sections revealed 
Figure 8. BME cell invasion of fibrin gels. BME cells grown to confluence on the surface of fibrin gels in the presence of Trasylol were 
treated with bFGF or TGF-/~I or both agents together for 7 d. (a, c, e, g) Phase-contrast microscopy; (b, d, f, h) semi-thin sections. (a 
and b) In control cultures, cells are seen to be confined to the surface of the gel. (c) In cultures treated with bFGF, by focusing beneath 
the surface monolayer, a network of interconnecting tube-like structures is seen (arrowheads  indicate lumen-like translucent spaces). (d) 
Semi-thin sections of bFGF-treated cultures reveal vessel-like structures, as weU as tubular invaginations of the surface monolayer into 
The Journal  of Cell Biology,  Volume 111, 1990  748 the underlying fibrin gel. (e and f) After treatment with TGF-/~I, cells are seen to be confined to the surface of the gel, and are more 
elongated than in controls. (8 and h) Simultaneous addition of bFGF and TGF-/31 inhibits the formation of tube-like structures seen in 
c and d, and results instead in the penetration of apparently solid endothelial cell cords lacking a lumen (arrowheads)  into the superficial 
part of the fibrin gel. Bars: (a, c, e, g)  10/~m;  (b, d, f, h) 50/tin. 
Pepper et al. Proteolytic Balance and Angiogenesis  749 Figure 9. Selected images from serial semi-thin sections of BME ceils on fibrin gels in the presence of Trasylol. (a-c) Cultures treated 
with bFGF and TGF-B1 for 7 d reveal invasion of BME cells into the superficial parts of the fibrin gel underneath the original monolayer, 
and the presence of solid endothelial cell cords connected with the surface monolayer. In marked contrast, cultures treated for 7 d with 
bFGF only in the presence of Trasylol (d-f), show widely patent lumina which also remain connected with the surface monolayer. Bar, 
50 ~m. 
that these solid cell cords remained associated with the sur- 
face monolayer (Fig. 9, a-c); in cultures treated with bFGF 
alone, a network of anastomosing tube-like structures with 
widely patent lumina connected to the  surface monolayer 
was seen on serial sections (Fig.  9, d-f). 
Since TGF-fll inhibits  bFGF-induced tube formation in a 
three-dimensional fibrin matrix,  the effect of simultaneous 
addition of the two agents on PAI-1 and u-PA mRNA levels 
was determined. An increase in PAI-1 and u-PA mRNA lev- 
els similar to the maximal increase after exposure to either 
TGF-/31 or  bFGF  alone,  was  seen  after  addition  of both 
agents together (Fig.  10). 
Changes  in  proteolytic  potential  were  represented  by 
changes in the ratio of u-PA:PAI-1 mRNA levels  at various 
times after treatment with bFGF or TGF-/~I (Fig.  11). At all 
time points considered, bFGF induced a net proteolytic re- 
sponse.  In contrast, TGF-~I induced an antiproteolytic re- 
sponse, which was maximal after 4 h (Fig. 11). Simultaneous 
The Journal of Cell Biology,  Volume 111, 1990  750 Figure I0. Effect of simultaneous addition of bFGF and TGF-/~  1 on 
u-PA and PAI-I steady-state mRNA levels. Northern  blots of total 
cellular RNA from BME cells exposed to either bFGF (F), TGF-/~I 
(T), or both agents simultaneously (F/T) for 12 h. (C) Control cul- 
tures. When both agents were added together, the increase in PAI-1 
and u-PA mRNA were similar to the maximal increase seen with 
either  TGF-/31 or bFGF alone.  Hybridization  of the  same filters 
with a rat actin probe reveals the presence of equal quantities of 
mRNA for cytoplasmic (8 and ~/) actins under all conditions tested. 
50. 
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Figure 11. Potential proteolytic balance as reflected by the ratio of 
u-PA:PAI-1 mRNAs. The values for each mRNA, and hence the ra- 
tio, were arbitrarily taken to be 1 at time =  0. After exposure to 
bFGF, an increase in potential proteolytic activity is observed over 
12 h.  In contrast,  TGF-/31 induces a decrease  in the u-PA:PAI-1 
mRNA ratio which is maximal after 4 h. In control cultures and 
in cultures exposed to both agents simultaneously, a small increase 
in u-PA:PAI-1 mRNA ratio is observed after 12 h. Values for con- 
trol, bFGF,  and TGF-/31-treated cultures  are derived  from those 
addition of these two agents resulted in a  small increase in 
proteolytic potential,  similar to that seen in untreated cul- 
tures (Fig.  11). 
Large Vessel Endothelial Cell Proteolytic Balance Is 
also Correlated with Angiogenic Properties 
To assess whether the correlation between proteolytic and 
angiogenic  properties  is  confined  to  microvascular  en- 
dothelial cells, we determined the effects of bFGF and TGF- 
/~1  on PA and  PAI-1 production and  fibrin gel invasion by 
CPAE cells. We have previously shown that these cells are 
capable of forming tube-like structures in collagen gels when 
stimulated with PMA in vitro (Montesano and Orci, 1987). 
Zymographic and  reverse  zymographic  analysis  revealed 
that bFGF (30 ng/ml) increased u-PA and decreased PAI-1 
production,  while  TGF-/ffl  (5  ng/ml)  increased  PAI-1  and 
completely inhibited u-PA production by these cells (Fig. 12, 
a  and b).  These findings are essentially reproduced at the 
mRNA level after exposure to bFGF (10 ng/ml) or TGF-/~I 
(1 ng/ml) for 12 h (Fig. 12 c). Thus, although levels of PAl-1 
and  u-PA  activity and  mRNA in  CPAE  cells  are  affected 
differently by bFGF and TGF-/31 when compared to BME 
cells, the difference in net proteolytic balance resulting from 
exposure to these two agents mimics the net effects seen in 
BME cells. 
CPAE cells were grown to confluence on the  surface of 
three-dimensional fibrin gels in the presence of Trasylol, and 
treated with bFGF (30 ng/ml); this resulted in invasion and 
formation of tube-like structures within the fibrin gel (Fig. 
13).  Addition of TGF-~I (5 ng/ml) inhibited bFGF-induced 
tube formation;  instead,  solid endothelial  cell  cords were 
seen to penetrate into the superficial parts of the fibrin gel 
(Fig.  13), thereby mimicking the effect of TGF-~ on bFGF- 
induced fibrin gel invasion by BME cells. 
Discussion 
The studies reported in this paper were prompted by two ap- 
parently  conflicting  observations:  (a)  bFGF-induced  inva- 
sion of the explanted aceUular amnion membrane by micro- 
vascular endothelial cells can be prevented by PA and plasmin 
inhibitors (Mignatti et al., 1989); and (b) bFGF increases PA 
inhibitor production by the same cells (Saksela et al., 1987). 
In the present study, we have found that bFGF, PMA,  and 
vanadate, three agents that induce endothelial cells to form 
capillary-like tubes in vitro (reviewed in Montesano et al., 
1990a) and to increase PA production (Gross et al.,  1982, 
1983; Montesano et al.,  1986; Moscatelli,  1986; Moscatelli 
et al.,  1986;  Presta et al.,  1986;  Montesano et al.,  1988), 
also induce the production of PAId and PAl-1 mRNA in BME 
cells. In addition, we observed that TGF-~, an agent which 
in vitro inhibits  PMA-induced  endothelial  cell invasion of 
collagen gels (Miiller et al.,  1987) and bFGF-induced inva- 
sion of the amnion membrane (Mignatti et al.,  1989),  also 
increases both u-PA and PAId mRNA levels in microvascu- 
lar endothelial  cells.  Thus,  both protease and antiprotease 
production are increased by agents that induce or inhibit mi- 
shown in Figs. 2 and 4, while values for the addition of both agents 
are from an experiment for which the 12-h time point is shown in 
Fig.  10. 
Pepper et al. Proteolytic  Balance and Angiogenesis  751 Figure 12.  PAId and u-PA induction in CPAE ceils. (a and b) 
Zymographic and reverse zymographic analysis of CPAE culture 
supernatant and cells. Zymographic analysis reveals an increase in 
u-PA after treatment of  CPAE  cells with bFGF, and a complete inhi- 
bition of u-PA production by TGF-B1 (a). Reverse zymographic 
analysis reveals an increase in PAI-I after treatment with TGF-/~I, 
and a small decrease in PAId after treatment with bFGF (b). (c) 
Northern blots of  total cellular CPAE  RNA hybridized with labeled 
mouse u-PA and bovine PAId (PI-OI) cRNA probes reveal an in- 
crease in u-PA and a decrease in PAI-I mRNA after 12 h of treat- 
ment with bFGE In contrast, TGF-/5  decreases u-PA and increases 
PAl-1 mRNA after 12 h. 
crovascular endothelial cell invasion in vitro. However,  we 
show that the magnitude and kinetics of the changes in PAId 
and u-PA mRNA levels in response to these different agents 
are strikingly different, bFGF and TGF-/~ cause a rapid and 
sustained elevation in u-PA and PAI-1 mRNA levels, respec- 
tively. In contrast, the effect of bFGF on PAId gene expres- 
sion is transitory, and that of TGF-BI on u-PA mRNA is de- 
layed, suggesting secondary mechanisms of regulation. Our 
results demonstrate that bFGF induces a net positive change 
in the proteolytic balance at all times analyzed, while "I'GF-/~ 
causes a marked and rapid antiproteolytic response; when 
bFGF and TGF-B1 are added simultaneously, the overall pro- 
teolytic potential is not different from that of control cultures. 
Utilizing our previously described model of  in vitro angio- 
genesis  (Montesano  and  Orci,  1985;  Montesano  et  al., 
1987),  we observed that bFGF induces microvascular en- 
dothelial  cells  to  form  tubular  capillary-like  structures 
within a three-dimensional fibrin gel, and that tube forma- 
tion can be completely inhibited by addition of 5 ng/ml of 
TGF-BI. This effect  of TGF-~ is unlikely to be due to inhibi- 
tion of endothelial cell  proliferation (Baird  and  Durkin, 
1986;  Fr~tter-Schrtder et al.,  1986;  Miiller et al.,  1987), 
since inhibition of DNA synthesis by mitomycin C treatment 
does not prevent the formation of tube-like structures in- 
duced by PMA in collagen gels (Montesano and Orci, 1985) 
or by bFGF in fibrin gels (our unpublished observations). 
TGF-B has also been shown to inhibit endothelial cell migra- 
tion in two dimensions (Heimark et al., 1986; Mtiller et al., 
1987;  Sato and Rifldn,  1989);  however,  the observations 
reported in our study indicate that migration into the fibrin 
matrix was not prevented, although it was limited to the su- 
perficial parts of the gel. In this regard, our results are in 
agreement with reports that TGF-B decreases the extent of 
PMA-induced invasion of a collagen gel (Miiller et al., 1987; 
R. Montesano, unpublished observation) and bFGF-induced 
invasion of the amnion membrane (Mignatti et al.,  1989). 
Modification of mRNA for cytoskeletal proteins by TGF-BI, 
and more specifically, induction of c~-actin mRNA, has been 
reported for rat epididymal fat pad microvascular endothelial 
cells (Kocher and Madri,  1989);  although this and subse- 
quent posttranscriptional modifications of actin expression 
might affect tube formation, we have not observed an induc- 
tion of o~-actin in BME cells after treatment with TGF-BI 
(our unpublished observation). Other effects of TGF-B not 
addressed in our present studies, such as modulation of ex- 
tracellular matrix adhesion receptors (Ignotz and Massagut, 
1987;  Heino et al.,  1989)  or endothelial cell extraceUular 
matrix protein synthesis (Miiller et al.,  1987; Madri et al., 
1988) by TGF-BI, might conceivably affect tube formation in 
our system. 
In view of the striking correlation between tube formation 
and positive changes in the proteolytic balance, inhibition of 
tube formation by TGF-ffl might be related to a decrease in 
the net proteolytic activity of endothelial cells, which is me- 
diated by an increase in PAl-1 production. Invasion into the 
superficial parts of the fibrin matrix in vitro by solid cords 
of endothelial cells, as observed after simultaneous treat- 
ment with bFGF and TGF-/51, may be less susceptible to an- 
tiproteases, since it may require more limited degradation of 
the substrate than the formation of large tubular structures 
containing widely patent lumina. 
Our present results must be considered in the context of 
previously reported effects of TGF-B on components of the 
angiogenic response. In vivo, TGF-~ is angiogenic when in- 
jected subcutaneously into adult mice (Roberts et al., 1985), 
a response that may be mediated by secretory products of 
TGF-B-recruited monocytes (Wisemann et al., 1988), there- 
by suggesting that the angiogenic effect  of subcutaneously in- 
jected TGF-B is indirect. However,  as a direct-acting agent 
in vitro, TGF-B inhibits endothelial cell replication (Baird 
The Journal of Cell Biology, Volume  111, 1990  752 Figure 13. Large vessel endothelial (CPAE) cell invasion of fibrin gels (phase-contrast microscopy). CPAE ceils grown to confluence on 
the surface of fibrin gels in the presence of Trasylol were treated with bFGF, TGF-fll, or both agents simultaneously for 7 d. (a) In control 
cultures, the ceils remain confined to the surface of the gel. (b) By focusing beneath the surface monolayer, large tube-like structures are 
seen after treatment with bFGE (c) In TGF-fll-treated cultures, cells remain confined to the surface of the gel, and are more elongated 
than in control cultures. (d) Treatment with both bFGF and TGF-fll. Focusing beneath the surface monolayer does not reveal the large 
tube-like structures seen after treatment with bFGF. Instead, solid endothelial cell cords (arrowheads), which penetrate into the superficial 
parts of the fibrin gel, are seen. Bar, 10/zm. 
and Durkin, 1986; Fr~ter-Schr'6der et al., 1986) and migra- 
tion (Heimark et al., 1986; MOiler et al., 1987). The inhibi- 
tory effects of  pericytes and smooth muscle cells on endothe- 
lial cell replication and migration (Antonelli-Orlidge et al., 
1989;  Sato and Rifkin,  1989) and of chondrocytes on en- 
dothelial sprout formation (Pepper, M.  S., R.  Montesano, 
J.-D. Vassalli, and L. Orci, manuscript submitted for publi- 
cation) in coculture, are also mediated by TGF-fl. TGF-/3 also 
has  a  direct inhibitory effect on endothelial cell invasion 
(MOiler  et  al.,  1987;  Mignatti  et  al.,  1989)  and  bFGF- 
induced tube formation (this study) in vitro.  However, the 
role of TGF-fl in vessel formation appears to be more com- 
plex than the studies mentioned above would suggest. It has 
been shown that when endothelial ceils are cultured within 
a  three-dimensional collagen gel and  subsequently treated 
with TGF-/31, gel contraction and organization of the cells 
into tube-like structures with tight junctions and albuminal 
basal lamina is promoted (Madri et al., 1988; Merwin et al., 
1990). In addition, we have observed that lower concentra- 
tions of TGF-/31 potentiate bFGF-induced invasion of  collagen 
and fibrin gels (Pepper, M. S., R. Montesano, J.-D. Vassalli, 
and  L.  Orci,  manuscript  in preparation).  Taken together, 
these apparently conflicting results might be reconciled by 
considering that  TGF-/3  could have different functions on 
vessel formation at different stages of the angiogenic pro- 
cess. Thus, it may modulate de novo FGF-induced invasion 
and inhibit vessel formation in specific and appropriate set- 
tings. Once sprout formation has occurred, TGF-fl might in- 
duce vessel organization and functional maturation, includ- 
ing the production of  a basal lamina, in immature new vessels. 
Mignatti et al.  (1989) found that bFGF-induced invasion 
of an acellular amnion membrane was characterized by the 
presence of elongated endothelial cells in the stroma. Since 
the amniotic membrane consists of a basement membrane 
and a thick collagenous stroma which is not normally vas- 
cularized, the amnion assay appears to be best suited to in- 
vestigations of endothelial cell invasiveness.  On the other 
hand, our in vitro models of collagen or fibrin gel invasion 
recapitulate in vitro another essential component of the pro- 
cess of angiogenesis, namely lumen formation. With respect 
to the role of proteolysis in the angiogenic response of en- 
dothelial cells, the amnion invasion assay (Mignatfi et al., 
1989) and our fibrin gel system suggest that two of the neces- 
sary steps in the angiogenic process, namely extracellular 
matrix invasion and tube formation, are events which both 
appear to require proteolysis. Furthermore, these two models 
demonstrate that matrix invasion and tube formation are sep- 
arable events which can be studied independently in vitro. 
Pepper et al. Proteolytic Balance and Angiogenesis  753 In conclusion, although correlative, our results  suggest a 
model  for  capillary  tube  formation  in  three-dimensional 
fibrin gels. Low levels of cell-associated proteolytic activity 
may be sufficient for invasion of this extracellular matrix, as 
demonstrated  by  the  formation of solid endothelial  cords 
within the superficial parts of the gel in the presence of both 
bFGF and TGF-/31. Tube formation may require higher levels 
of proteolysis so that a space or cavity can be formed, which 
becomes lined with endothelial cells in the process of creat- 
ing a vessel-like structure with a patent lumen. Uncontrolled 
proteolysis would result in excessive matrix destruction, and 
hence prevent  the formation of normal vascular  structures 
(Montesano et al., 1987, 1990b). Thus, the interplay between 
bFGF and TGF-~ could be critical to achieve a proteolytic 
balance which is appropriate  for normal capillary morpho- 
genesis. 
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